ImmunityBio Balance Sheet Health
Financial Health criteria checks 0/6
ImmunityBio has a total shareholder equity of $-585.9M and total debt of $838.4M, which brings its debt-to-equity ratio to -143.1%. Its total assets and total liabilities are $504.5M and $1.1B respectively.
Key information
-143.1%
Debt to equity ratio
US$838.43m
Debt
| Interest coverage ratio | n/a |
| Cash | US$266.46m |
| Equity | -US$585.94m |
| Total liabilities | US$1.09b |
| Total assets | US$504.45m |
Recent financial health updates
No updates
Recent updates
ImmunityBio Lights Up: Anktiva's FDA Nod Shakes Up Bladder Cancer Battle
Apr 23ImmunityBio: Financial And Regulatory Risks Outweigh Anktiva's Promise
Feb 27ImmunityBio: Buy Low Now Vs. Buy High Later
Feb 11ImmunityBio: PDUFA Pending
Oct 17ImmunityBio: Compelling Data In Bladder Cancer, Yet Funding Issues Remain
Aug 07ImmunityBio: Ready To Shift Gears After Long-Awaited BLA Submission
Jun 02ImmunityBio: Extensive Pipeline, NDA Expected For Anktiva This Quarter
Mar 15ImmunityBio: Company Leaves 2021 On A High-Note; Share Price Still Falls Flat
Dec 27ImmunityBio: Demoralization Of The Bulls By Deflating The Share Price
Oct 12ImmunityBio: Market Has Lost Contact Following Merger
Jul 19ImmunityBio posts results from early-stage blood cancer study
May 04Financial Position Analysis
Short Term Liabilities: IBRX has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: IBRX has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: IBRX has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: IBRX's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: IBRX has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: IBRX has less than a year of cash runway if free cash flow continues to reduce at historical rates of 26.2% each year